{"organizations": [], "uuid": "8483e3c42f381cc2c7a9e0dcd52b76f68e2895df", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-clearside-biomedical-announces-res/brief-clearside-biomedical-announces-results-from-phase-3-trial-of-cls-ta-idUSASB0C8PV", "country": "US", "domain_rank": 408, "title": "BRIEF-Clearside Biomedical Announces Results From Phase 3 Trial Of CLS-TA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.195, "site_type": "news", "published": "2018-03-05T20:16:00.000+02:00", "replies_count": 0, "uuid": "8483e3c42f381cc2c7a9e0dcd52b76f68e2895df"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-clearside-biomedical-announces-res/brief-clearside-biomedical-announces-results-from-phase-3-trial-of-cls-ta-idUSASB0C8PV", "ord_in_thread": 0, "title": "BRIEF-Clearside Biomedical Announces Results From Phase 3 Trial Of CLS-TA", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "clearside biomedical inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "macular edema", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Clearside Biomedical Inc:\n* CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF CLS-TA IN MACULAR EDEMA ASSOCIATED WITH NON-INFECTIOUS UVEITIS\n* PRIMARY ENDPOINT ACHIEVED IN PHASE 3 CLINICAL TRIAL OF CLS-TA\n* ALL KEY SECONDARY ENDPOINTS ACHIEVED IN STUDY * STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROPORTION OF PATIENTS GAINING 15 OR MORE LETTERS IN VISUAL ACUITY IN STUDY\n* SUPRACHOROIDAL CLS-TA WAS GENERALLY WELL TOLERATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED IN TRIAL\n* EXPECT TO SUBMIT NDA FOR SUPRACHOROIDAL CLS-TA IN PATIENTS WITH MACULAR EDEMA ASSOCIATED WITH UVEITIS TO FDA IN Q4 2018\n* EVALUATING OPTIONS FOR SUBMISSIONS TO REGULATORY AGENCIES IN TERRITORIES OUTSIDE OF U.S. FOR SUPRACHOROIDAL CLS-TA Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T20:16:00.000+02:00", "crawled": "2018-03-06T22:31:45.006+02:00", "highlightTitle": ""}